Aptahem enters consortium together with Örebro University, AnaMar AB and Dalhousie University


Aptahem (publ) today announced that the company now enters a consortium together with Örebro University, the pharmaceutical development company AnaMar and Dalhousie University in Canada. The newly established consortium aims to evaluate new strategies to reduce inflammation, thrombosis and...

Read More

Aptahem announces strengthened research results with Apta-1 from completed NHP study


Aptahem (publ) today announce positive final results from the exploratory sepsis study with non human primates, the NHP study. The new preclinical results continue to support Apta-1’s multifunctional drug candidate potential within the treatment of sepsis. The completed comprehensive...

Read More

Aptahem present preclinical progress of the company’s lead candidate Apta-1 at the world’s largest conference for intensive care


Aptahem (publ) announced today that a presentation entitled “Apta-1, a novel RNA aptamer, improves outcome in an animal model of sepsis” will be held at the World Congress of Intensive Care in Melbourne, Australia, October 14-18, 2019. This conference...

Read More

Aptahem signs agreement with new contract manufacturer


Aptahem (publ) announced today that the company has signed an agreement with a GMP-certified (Good Manufacturing Practice) contract manufacturer, LGC Group. LGC Group will manufacture the company’s lead candidate, Apta-1, for the concluding toxicological studies and the production is...

Read More

Aptahem’s cooperation with Seattle Children’s Hospital increases the understanding of Apta-1


Aptahem (publ), a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved, announces today that the cooperation with the Seattle Children’s Hospital has now generated the...

Read More

Aptahems latest patent application is published


Aptahem today informs that the company’s latest patent application has been made public. The patent application, which is an international PCT application*, is a merger of two previous Europe applications with the priority date 3 October 2017. The patent...

Read More

Aptahem confirms CMO Dr. Bylock’s responsibilities


Aptahem (publ) announced today that Dr. Anders Bylock, Chief Medical Officer (CMO), is taking on another part-time position effective immediately. Dr Bylock engagement with the company as CMO as well as chairman of the scientific advisory board is unchanged...

Read More

Aptahem reports delay in delivery of its drug product


Aptahem (publ) announced today that manufacture of its drug product has been delayed as a result of technical challenges. As a consequence, Aptahem anticipates that commencement of the planned clinical study for Apta-1 will be delayed. Aptahem reports that...

Read More

Aptahem recalls outstanding convertible notes to Yorkville


Aptahem AB (publ) today announces that the company intends to recall the outstanding amount of convertible notes held by YA II PN Ltd, a fund represented by the U.S.-based Yorkville Advisors Global (”Yorkville”). Through a mutual agreement, Aptahem will...

Read More

Endpoints News article: Aptahem – a Swedish biotech aiming to win the race against sepsis


In the fight to save a person affected by sepsis every second counts – each hour that passes increases the risk of death with 8 percent. It is literally a race against time, a race that the healthcare services...

Read More